Exclusive Summary

• - Core patents largely expired globally in 2014–2017, and 0.5 mg generics face no major patent barriers in most markets.
• - ~254 million people live with chronic HBV, ~1.1 million deaths/year, and only ~3% receive treatment; 0.5 mg fits the treatment-naïve majority with large upside.
• - Listed on the WHO EML and recommended as first-line/preferred by WHO/AASLD/EASL; <1% 5‑year resistance in naïve patients and renal/bone safety advantages.
• - Highly competitive with ≥20 US ANDAs and broad EU/EM access; differentiation hinges on high-quality CTD+BE, Zone IVb stability, and reliable supply.
• - Versus originator, typical 80–95% price reduction; large tenders can reach ~$0.05–0.20/tablet or <$5–10/month (market- and volume-dependent), enabling strong price competitiveness.

Asset Materials

Contact Us for Full Materials